AstraZeneca: Farxiga gets FDA fast-track status
(CercleFinance.com) - AstraZeneca said on Monday that the U.
S. Food and Drug Administration has granted "fast track" status for its diabetes drug Farxiga in heart failure.
The FDA has granted this designation for the development of Farxiga to reduce the risk of cardiovascular death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction or preserved ejection fraction, the Anglo-Swedish drugmaker said.
The FDA grants fast track status to drugs intended to treat serious conditions where there is an unmet need for treatment.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
S. Food and Drug Administration has granted "fast track" status for its diabetes drug Farxiga in heart failure.
The FDA has granted this designation for the development of Farxiga to reduce the risk of cardiovascular death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction or preserved ejection fraction, the Anglo-Swedish drugmaker said.
The FDA grants fast track status to drugs intended to treat serious conditions where there is an unmet need for treatment.
Copyright (c) 2019 CercleFinance.com. All rights reserved.